Pharmacokinetic (PK) Bioequivalence And Comparable Efficacy/Safety Were Demonstrated With Pearl Therapeutics' Formoterol Fumarate MDI (FF-MDI, PT005) Compared To Foradil® Aerolizer® In A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study In Patients With Moderate To Very-Severe Chronic Obstructive Pulmonary Disease